(33)Commission Implementing Regulation (EU) 2023/2592note extended the approval periods of the active substances 1-naphthylacetamide, 1-naphthylacetic acid, fluazifop-P, prohexadione, spiroxamine and esfenvalerate until 31 May 2026.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.